Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
Piñana JL, Martino R, Vazquez L, López-Corral L, Pérez A, Chorão P, Avendaño-Pita A, Pascual MJ, Sánchez-Salinas A, Sanz-Linares G, Olave MT, Arroyo I, Tormo M, Villalon L, Conesa-Garcia V, Gago B, Terol MJ, Villalba M, Garcia-Gutierrez V, Cabero A, Hernández-Rivas JÁ, Ferrer E, García-Cadenas I, Teruel A, Navarro D, Cedillo Á, Sureda A, Solano C; Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). Piñana JL, et al. Among authors: olave mt. Bone Marrow Transplant. 2023 May;58(5):567-580. doi: 10.1038/s41409-023-01946-0. Epub 2023 Feb 28. Bone Marrow Transplant. 2023. PMID: 36854892 Free PMC article.
SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
Piñana JL, López-Corral L, Martino R, Montoro J, Vazquez L, Pérez A, Martin-Martin G, Facal-Malvar A, Ferrer E, Pascual MJ, Sanz-Linares G, Gago B, Sanchez-Salinas A, Villalon L, Conesa-Garcia V, Olave MT, López-Jimenez J, Marcos-Corrales S, García-Blázquez M, Garcia-Gutiérrez V, Hernández-Rivas JÁ, Saus A, Espigado I, Alonso C, Hernani R, Solano C, Ferrer-Lores B, Guerreiro M, Ruiz-García M, Muñoz-Bellido JL, Navarro D, Cedillo A, Sureda A; Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). Piñana JL, et al. Among authors: olave mt. Am J Hematol. 2022 Jan 1;97(1):30-42. doi: 10.1002/ajh.26385. Epub 2021 Nov 2. Am J Hematol. 2022. PMID: 34695229 Free PMC article.
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders.
Piñana JL, López-Corral L, Martino R, Vazquez L, Pérez A, Martin-Martin G, Gago B, Sanz-Linares G, Sanchez-Salinas A, Villalon L, Conesa-Garcia V, Olave MT, Corona M, Marcos-Corrales S, Tormo M, Hernández-Rivas JÁ, Montoro J, Rodriguez-Fernandez A, Risco-Gálvez I, Rodríguez-Belenguer P, Hernandez-Boluda JC, García-Cadenas I, Ruiz-García M, Muñoz-Bellido JL, Solano C, Cedillo Á, Sureda A, Navarro D; Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). Piñana JL, et al. Among authors: olave mt. J Hematol Oncol. 2022 May 7;15(1):54. doi: 10.1186/s13045-022-01275-7. J Hematol Oncol. 2022. PMID: 35526045 Free PMC article.
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients.
Piñana JL, Vazquez L, Calabuig M, López-Corral L, Martin-Martin G, Villalon L, Sanz-Linares G, Conesa-Garcia V, Sanchez-Salinas A, Gago B, Facal A, Risco-Gálvez I, Olave MT, Espigado I, Lopez-Jimenez J, Hernández-Rivas JÁ, Avendaño-Pita A, Arroyo I, Ferrer E, García-Cadenas I, González-Santillana C, Roldán-Pérez A, Ferrer B, Guerreiro M, Suarez-Lledó M, Camara A, Campos-Beltrán D, Navarro D, Cedillo Á, Sureda A, Solano C; Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC); Martino R. Piñana JL, et al. Among authors: olave mt. Blood Cancer J. 2023 Jan 5;13(1):8. doi: 10.1038/s41408-022-00778-3. Blood Cancer J. 2023. PMID: 36599843 Free PMC article.
Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
Piñana JL, Rodríguez-Belenguer P, Caballero D, Martino R, Lopez-Corral L, Terol MJ, Vazquez L, Calabuig M, Sanz-Linares G, Marin-Jimenez F, Alonso C, Montoro J, Ferrer E, Facal A, Pascual MJ, Rodriguez-Fernandez A, Olave MT, Cascales-Hernandez A, Gago B, Hernández-Rivas JÁ, Villalon L, Corona M, Roldán-Pérez A, Ribes-Amoros J, González-Santillana C, Garcia-Sanz R, Navarro D, Serrano-López AJ, Cedillo Á, Soria-Olivas E, Sureda A, Solano C; Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). Piñana JL, et al. Among authors: olave mt. Ann Hematol. 2022 Sep;101(9):2053-2067. doi: 10.1007/s00277-022-04906-8. Epub 2022 Jul 2. Ann Hematol. 2022. PMID: 35780254 Free article.
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group.
Palanques-Pastor T, Megías-Vericat JE, Martínez P, López Lorenzo JL, Cornago Navascués J, Rodriguez Macias G, Cano I, Arnan Sangerman M, Vidriales Vicente MB, Algarra Algarra JL, Foncillas MÁ, Herrera P, Botella Prieto C, Vives S, Figuera Álvarez Á, Cuevas Palomares L, Sobas M, Contento Gonzalo A, Cuello García R, Amutio Diez ME, De Miguel Llorente D, Navas Elorza B, Bergua Burgues JM, Bernal Del Castillo T, Mateos Rodríguez MC, de Cabo López E, Franco Villegas AC, García Boyero R, Escolano Escobar C, Seri Merino C, Cervero C, Roldán Pérez A, Hermosín Ramos L, Cervera Calvo M, Olave MT, Villafuerte Gutiérrez P, de Laiglesiai A, Serrano J, Najera Irazu MJ, Piñana JL, Sanz MÁ, Martínez-López J, Montesinos P. Palanques-Pastor T, et al. Among authors: olave mt. Leuk Lymphoma. 2021 Dec;62(12):2928-2938. doi: 10.1080/10428194.2021.1948031. Epub 2021 Jul 22. Leuk Lymphoma. 2021. PMID: 34292118
Survival Outcomes and Health-Related Quality of Life in Older Adults Diagnosed with Acute Myeloid Leukemia Receiving Frontline Therapy in Daily Practice.
Ramos F, Hermosín ML, Fuertes-Núñez M, Martínez P, Rodriguez-Medina C, Barrios M, Ibáñez F, Bernal T, Olave MT, Álvarez MÁ, Vahí M, Caballero-Velázquez T, González B, Altés A, García L, Fernández P, Durán MA, López R, Rafel M, Serrano J. Ramos F, et al. Among authors: olave mt. J Pers Med. 2023 Nov 28;13(12):1667. doi: 10.3390/jpm13121667. J Pers Med. 2023. PMID: 38138894 Free PMC article.
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.
Castaño-Bonilla T, Barragán E, Sargas C, Sanz A, Algarra L, Herrera-Puente P, García-Boyero R, Barrios M, Martinez-Cuadron D, Rodriguez-Veiga R, Boluda B, Gil C, Serrano-López J, Martínez-López J, Sayas-Lloris MJ, Olave MT, Riaza-Grau R, Castillo TB, Larrayoz MJ, Amigo R, Jiménez-Velasco A, Sánchez J, Ayala R, Blas C, Lainez D, Serrano-López J, Sanz MA, Alonso-Domínguez JM, Montesinos P. Castaño-Bonilla T, et al. Among authors: olave mt. Dis Markers. 2022 Aug 23;2022:3132941. doi: 10.1155/2022/3132941. eCollection 2022. Dis Markers. 2022. PMID: 36051360 Free PMC article.
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.
Castaño-Bonilla T, Alonso-Dominguez JM, Barragán E, Rodríguez-Veiga R, Sargas C, Gil C, Chillón C, Vidriales MB, García R, Martínez-López J, Ayala R, Larrayoz MJ, Anguita E, Cuello R, Cantalapiedra A, Carrillo E, Soria-Saldise E, Labrador J, Recio I, Algarra L, Rodríguez-Medina C, Bilbao-Syeiro C, López-López JA, Serrano J, De Cabo E, Sayas MJ, Olave MT, Sánchez-García J, Mateos M, Blas C, López-Lorenzo JL, Lainez-Gonzalez D, Serrano J, Martínez-Cuadrón D, Sanz MA, Montesinos P. Castaño-Bonilla T, et al. Among authors: olave mt. Sci Rep. 2021 Oct 20;11(1):20745. doi: 10.1038/s41598-021-00050-x. Sci Rep. 2021. PMID: 34671057 Free PMC article.
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Vives S, Martínez-Cuadrón D, Bergua Burgues J, Algarra L, Tormo M, Martínez-Sánchez MP, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, López-Lorenzo JL, Gil C, Vidriales B, Falantes JF, Serrano A, Labrador J, Sayas MJ, Foncillas MÁ, Amador Barciela ML, Olave MT, Colorado M, Gascón A, Fernández MÁ, Simiele A, Pérez-Encinas MM, Rodríguez-Veiga R, García O, Martínez-López J, Barragán E, Paiva B, Sanz MÁ, Montesinos P; PETHEMA Group. Vives S, et al. Among authors: olave mt. Cancer. 2021 Jun 15;127(12):2003-2014. doi: 10.1002/cncr.33403. Epub 2021 Feb 24. Cancer. 2021. PMID: 33626197 Free article. Clinical Trial.
20 results